Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Capreomycin is active against non-replicating M. tuberculosis.

Leonid Heifets1, Julie Simon, Van Pham

  • 1National Jewish Medical and Research Center, Denver, Colorado 80206, USA. HeifetsL@njc.org

Annals of Clinical Microbiology and Antimicrobials
|April 5, 2005
PubMed
Summary

Capreomycin demonstrated significant bactericidal activity against non-replicating Mycobacterium tuberculosis in vitro, similar to metronidazole. This finding suggests potential for peptide antibiotics in treating latent tuberculosis infection (LTBI).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Performance of a targeted next generation sequencing assay for mycobacterial identification and drug resistance from sputum and isolates.

Journal of clinical microbiology·2026
Same author

Germline variants in cancer susceptibility genes among patients with mucosal melanoma.

NPJ genomic medicine·2026
Same author

Specialized gas-exchange endothelium of the zebrafish gill.

bioRxiv : the preprint server for biology·2026
Same author

Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program pilot study.

Cancer·2026
Same author

Investigating Chronic Toxicity, Diet, Patient-Reported Outcomes and the Microbiome in Immunotherapy-Treated Metastatic Melanoma Survivors: A New Frontier.

Nutrients·2026
Same author

SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade.

Nature·2025

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Latent tuberculosis infection (LTBI) affects one-third of the global population.
  • Activation of LTBI is a major source of new tuberculosis cases.
  • LTBI involves non-replicating Mycobacterium tuberculosis (M. tuberculosis).

Purpose of the Study:

  • To evaluate the in vitro activity of various antimicrobial agents against non-replicating M. tuberculosis.
  • To identify potential treatments for the persistent, non-replicating form of tuberculosis.

Main Methods:

  • M. tuberculosis strains were cultured under anaerobic conditions to induce a non-replicating state (NRP).
  • 32 antimicrobial agents, including all known anti-TB drugs, were tested.
  • Bacterial viability was assessed by colony-forming units (CFU/ml) over time.

Related Experiment Videos

  • Metronidazole served as a positive control due to its known efficacy in anaerobic settings.

    • Main Results:

    • Metronidazole exhibited a clear bactericidal effect under anaerobic, non-replicating conditions.
    • Capreomycin was the only tested anti-TB drug to show comparable bactericidal activity to metronidazole.
    • No other tested antimicrobial agents demonstrated significant efficacy against non-replicating M. tuberculosis.

    Conclusions:

    • Capreomycin's unique in vitro bactericidal activity against non-replicating M. tuberculosis warrants further investigation.
    • Peptide antibiotics may represent a promising class for developing new anti-TB drugs.
    • Further research should explore capreomycin's mechanism of action and in vivo efficacy in animal models.